{"component": "definition", "props": {"groups": [{"samples": [{"hash": "fjroHrHZtUk", "uri": "/contracts/fjroHrHZtUk#technology-access-fee", "label": "Exclusive Channel Collaboration Agreement (Carisma Therapeutics Inc.)", "score": 36.5509924709, "published": true}, {"hash": "FqP4X806I2", "uri": "/contracts/FqP4X806I2#technology-access-fee", "label": "Exclusive Channel Collaboration Agreement (Castle Creek Biosciences, Inc.)", "score": 32.5373039246, "published": true}, {"hash": "21YulHc3wiS", "uri": "/contracts/21YulHc3wiS#technology-access-fee", "label": "Exclusive Channel Collaboration Agreement (Castle Creek Biosciences, Inc.)", "score": 32.4031486511, "published": true}], "size": 20, "snippet": "for the purposes of this Agreement has the meaning as set forth in Section 5.1.", "snippet_links": [{"key": "for-the-purposes-of-this-agreement", "type": "clause", "offset": [0, 34]}, {"key": "section-51", "type": "clause", "offset": [67, 78]}], "hash": "d5ec579e35670b3411c55b70e7d8957a", "id": 1}, {"samples": [{"hash": "eFfi8sGwcFw", "uri": "/contracts/eFfi8sGwcFw#technology-access-fee", "label": "Development and Option Agreement (Environmental Impact Acquisition Corp)", "score": 32.7973976135, "published": true}, {"hash": "anPBgzEbc7D", "uri": "/contracts/anPBgzEbc7D#technology-access-fee", "label": "Development and Option Agreement (Omega Therapeutics, Inc.)", "score": 32.5646820068, "published": true}, {"hash": "fSsdsZNf7ee", "uri": "/contracts/fSsdsZNf7ee#technology-access-fee", "label": "Development and Option Agreement (Omega Therapeutics, Inc.)", "score": 32.5181388855, "published": true}], "size": 7, "snippet": "has the meaning set forth in Section 3.4(d).", "snippet_links": [], "hash": "f308d9381dafb1bc931f03a3f60fccb7", "id": 2}, {"samples": [{"hash": "bUQDjISpoCv", "uri": "/contracts/bUQDjISpoCv#technology-access-fee", "label": "Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 34.3497619629, "published": true}, {"hash": "bHKMWrplZc7", "uri": "/contracts/bHKMWrplZc7#technology-access-fee", "label": "Collaboration and Commercial License Agreement", "score": 31.3408622742, "published": true}, {"hash": "df0ANPdsiJb", "uri": "/contracts/df0ANPdsiJb#technology-access-fee", "label": "Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 28.414100647, "published": true}], "size": 7, "snippet": "is defined in Section 6.1.", "snippet_links": [{"key": "section-61", "type": "clause", "offset": [14, 25]}], "hash": "f1e882964a8a4d102a7296f2e013dee4", "id": 3}, {"samples": [{"hash": "ktSdNvXeQ68", "uri": "/contracts/ktSdNvXeQ68#technology-access-fee", "label": "Licence and Development Agreement", "score": 29.3408622742, "published": true}, {"hash": "4CLqKVIgHOF", "uri": "/contracts/4CLqKVIgHOF#technology-access-fee", "label": "Licence and Development Agreement (Orchard Rx LTD)", "score": 27.7556476593, "published": true}, {"hash": "h6LnDqocl4S", "uri": "/contracts/h6LnDqocl4S#technology-access-fee", "label": "Licence and Development Agreement (Orchard Rx LTD)", "score": 27.7145786285, "published": true}], "size": 4, "snippet": "means a fee for utilising BioMedica\u2019s [***], which fee shall be [***] (or other such amount agreed between the Parties in writing or outlined in a statement of work signed by the Parties).", "snippet_links": [{"key": "agreed-between-the-parties", "type": "clause", "offset": [92, 118]}, {"key": "in-writing", "type": "definition", "offset": [119, 129]}, {"key": "statement-of-work", "type": "definition", "offset": [147, 164]}, {"key": "signed-by-the-parties", "type": "clause", "offset": [165, 186]}], "hash": "9a1540391d4aed9a3be03ab1548b857a", "id": 4}, {"samples": [{"hash": "8lEHrcDZcfg", "uri": "/contracts/8lEHrcDZcfg#technology-access-fee", "label": "Background Ip License Agreement (Monte Rosa Therapeutics, Inc.)", "score": 32.4223136902, "published": true}, {"hash": "l69ez72twSz", "uri": "/contracts/l69ez72twSz#technology-access-fee", "label": "Background Ip License Agreement (Monte Rosa Therapeutics, Inc.)", "score": 32.3264884949, "published": true}, {"hash": "ilPvhV7bZB1", "uri": "https://ir.monterosatx.com/static-files/d80a4004-ff10-483a-bb45-11ab2011d9d5", "label": "Amendment", "score": 14.7125253677, "published": false}], "size": 3, "snippet": "means [***].", "snippet_links": [], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 5}, {"samples": [{"hash": "emueGH1vj8H", "uri": "/contracts/emueGH1vj8H#technology-access-fee", "label": "Research Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 28.414100647, "published": true}, {"hash": "3Z24wfUhdVQ", "uri": "/contracts/3Z24wfUhdVQ#technology-access-fee", "label": "Research Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 28.2060241699, "published": true}], "size": 3, "snippet": "has the meaning set forth in Section 7.1.", "snippet_links": [{"key": "section-71", "type": "clause", "offset": [29, 40]}], "hash": "ceec2a0e4f5aa9ad79b9001b9b1d6448", "id": 6}, {"samples": [{"hash": "2Es5x7ywMXI", "uri": "/contracts/2Es5x7ywMXI#technology-access-fee", "label": "Strategic Collaboration and License Agreement (Isis Pharmaceuticals Inc)", "score": 26.338809967, "published": true}, {"hash": "kOGPgqThpPi", "uri": "https://ir.ionis.com/static-files/4cbbd908-99d7-403d-8262-69b998bd8d82", "label": "ir.ionis.com", "score": 14.748670578, "published": false}], "size": 3, "snippet": "means any payments that Alnylam receives from granting a Third Party access (through sublicense or otherwise) to the Isis Patent Rights (including to Isis Exclusive Target Patent Rights that are also Isis Patent Rights) as part of a Bona Fide Discovery Collaboration or Development Collaboration agreement, including, but not limited to, (1) license fees, (2) collaboration fees, (3) option fees, (4) payments made in consideration for the issuance of equity or debt securities above fair market value, (5) payments made for research and development support above Alnylam\u2019s fully-burdened cost, but excluding the following payments: (i) payments made in consideration for equity or debt securities of Alnylam at fair market value, (ii) payments made in consideration for thirty-five percent (35%) or more of Alnylam\u2019s equity securities at fair market value plus a reasonable control premium, (iii) payments specifically committed to reimburse Alnylam for the fully-burdened cost of research and development, including without limitation the fully-burdened cost of products transferred by Alnylam in connection with such research and development, and payments received by Alnylam pursuant to the Agbio License Agreement that are specifically committed to reimburse Alnylam for the cost of Patent prosecution, maintenance and/or defense of Patents covering or claiming Agricultural Field Products; provided, however, that any payments received by Alnylam but not applied to reimburse Alnylam for such expenses will be Technology Access Fees, (iv) [***] (v) payments that are not milestones and that are associated with the sale of commercial products, and (vi) payments that count as Sublicense Revenue under a Naked Sublicense subject to Alnylam\u2019s payment obligations to Isis under Section 7.4. If Alnylam receives any non-cash Technology Access Fees, Alnylam will pay Isis, at Isis\u2019 election, either (x) a cash payment equal to the fair market value of Isis\u2019 appropriate portion of the Technology Access Fee or (y) the in-kind portion, if practicable, of the Technology Access Fee.", "snippet_links": [{"key": "third-party-access", "type": "clause", "offset": [57, 75]}, {"key": "isis-patent-rights", "type": "clause", "offset": [117, 135]}, {"key": "target-patent-rights", "type": "definition", "offset": [165, 185]}, {"key": "bona-fide-discovery-collaboration", "type": "definition", "offset": [233, 266]}, {"key": "collaboration-agreement", "type": "definition", "offset": [282, 305]}, {"key": "not-limited", "type": "clause", "offset": [322, 333]}, {"key": "license-fees", "type": "clause", "offset": [342, 354]}, {"key": "option-fees", "type": "definition", "offset": [384, 395]}, {"key": "payments-made", "type": "clause", "offset": [401, 414]}, {"key": "in-consideration-for", "type": "clause", "offset": [415, 435]}, {"key": "issuance-of-equity", "type": "clause", "offset": [440, 458]}, {"key": "debt-securities", "type": "clause", "offset": [462, 477]}, {"key": "research-and-development-support", "type": "clause", "offset": [525, 557]}, {"key": "burdened-cost", "type": "definition", "offset": [580, 593]}, {"key": "but-excluding", "type": "clause", "offset": [595, 608]}, {"key": "five-percent", "type": "clause", "offset": [778, 790]}, {"key": "equity-securities", "type": "clause", "offset": [818, 835]}, {"key": "control-premium", "type": "definition", "offset": [875, 890]}, {"key": "to-reimburse", "type": "definition", "offset": [930, 942]}, {"key": "cost-of-research", "type": "clause", "offset": [974, 990]}, {"key": "including-without-limitation", "type": "clause", "offset": [1008, 1036]}, {"key": "cost-of-products", "type": "clause", "offset": [1056, 1072]}, {"key": "by-alnylam", "type": "clause", "offset": [1085, 1095]}, {"key": "in-connection-with", "type": "clause", "offset": [1096, 1114]}, {"key": "received-by", "type": "definition", "offset": [1159, 1170]}, {"key": "pursuant-to-the", "type": "definition", "offset": [1179, 1194]}, {"key": "agbio-license-agreement", "type": "definition", "offset": [1195, 1218]}, {"key": "the-cost", "type": "clause", "offset": [1276, 1284]}, {"key": "patent-prosecution", "type": "definition", "offset": [1288, 1306]}, {"key": "defense-of-patents", "type": "clause", "offset": [1327, 1345]}, {"key": "field-products", "type": "definition", "offset": [1380, 1394]}, {"key": "technology-access-fees", "type": "clause", "offset": [1516, 1538]}, {"key": "associated-with", "type": "definition", "offset": [1601, 1616]}, {"key": "sale-of", "type": "clause", "offset": [1621, 1628]}, {"key": "commercial-products", "type": "definition", "offset": [1629, 1648]}, {"key": "sublicense-revenue", "type": "definition", "offset": [1682, 1700]}, {"key": "naked-sublicense", "type": "definition", "offset": [1709, 1725]}, {"key": "subject-to", "type": "definition", "offset": [1726, 1736]}, {"key": "payment-obligations", "type": "definition", "offset": [1747, 1766]}, {"key": "section-74", "type": "clause", "offset": [1781, 1792]}, {"key": "any-non", "type": "clause", "offset": [1814, 1821]}, {"key": "cash-payment", "type": "definition", "offset": [1906, 1918]}, {"key": "equal-to", "type": "definition", "offset": [1919, 1927]}, {"key": "the-fair-market-value", "type": "clause", "offset": [1928, 1949]}, {"key": "the-technology", "type": "clause", "offset": [1982, 1996]}], "hash": "97ffa0ca6f6b38f19aa45a6d2a6fa296", "id": 7}, {"samples": [{"hash": "6qjjdA0WIzw", "uri": "/contracts/6qjjdA0WIzw#technology-access-fee", "label": "Settlement and License Agreement (Bioform Medical Inc)", "score": 21.0, "published": true}, {"hash": "5CDZwosatkq", "uri": "/contracts/5CDZwosatkq#technology-access-fee", "label": "Settlement and License Agreement (Artes Medical Inc)", "score": 21.0, "published": true}], "size": 3, "snippet": "shall have the meaning set forth in Section 4.", "snippet_links": [{"key": "in-section-4", "type": "clause", "offset": [33, 45]}], "hash": "5079c570484dd26535cb318475c8b105", "id": 8}, {"samples": [{"hash": "11tM8OLY2a2", "uri": "/contracts/11tM8OLY2a2#technology-access-fee", "label": "Research and Technology Agreement (Intrabiotics Pharmaceuticals Inc /De)", "score": 21.0, "published": true}], "size": 3, "snippet": "shall have the meaning set forth in Section 5.2.", "snippet_links": [{"key": "section-52", "type": "clause", "offset": [36, 47]}], "hash": "dd39f2ac9ed9d9e5cab1084d8022452e", "id": 9}, {"samples": [{"hash": "jSRib1UcC3f", "uri": "https://ir.ionispharma.com/static-files/14abb88a-3b91-422e-8137-39e430784197", "label": "ir.ionispharma.com", "score": 9.9637231827, "published": false}, {"hash": "Go1NczM8dO", "uri": "https://ir.ionispharma.com/static-files/fa960853-a1ba-4437-80d9-1fc8f60fc2ca", "label": "ir.ionispharma.com", "score": 9.6707735062, "published": false}], "size": 2, "snippet": "means any payments that Alnylam receives from granting a Third Party access (through sublicense or otherwise) to the Isis Patent Rights as part of a Bona Fide Collaboration or Development Collaboration agreement, including, but not limited to, (1) license fees,", "snippet_links": [{"key": "third-party-access", "type": "clause", "offset": [57, 75]}, {"key": "isis-patent-rights", "type": "clause", "offset": [117, 135]}, {"key": "bona-fide-collaboration", "type": "definition", "offset": [149, 172]}, {"key": "collaboration-agreement", "type": "definition", "offset": [188, 211]}, {"key": "not-limited", "type": "clause", "offset": [228, 239]}, {"key": "license-fees", "type": "clause", "offset": [248, 260]}], "hash": "2cf19b36187a57400772b23d82a10c52", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIedGVjaG5vbG9neS1hY2Nlc3MtZmVlIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 64, "title": "Technology Access Fee", "snippet": "for the purposes of this Agreement has the meaning as set forth in Section 5.1.", "id": "technology-access-fee", "examples": ["Provided that all closing conditions for the <strong>Technology Access Fee</strong> Shares (as defined in the Equity Agreements) that are within the reasonable control of Intrexon have been satisfied or waived, the issuance of the <strong>Technology Access Fee</strong> Shares (as set forth in the Equity Agreements) is a condition subsequent to the effectiveness of this Agreement.", "In the event that any payment, including royalty, milestone, Sublicense Revenue or <strong>Technology Access Fee</strong> payments, due hereunder is not made when due, the payment will bear interest from the date due at the lesser of (i) 1.5% per month, compounded monthly, or (ii) the highest rate permitted by law; provided, however, that in no event will such rate exceed the maximum legal annual interest rate.", "Provided that all closing conditions for the <strong>Technology Access Fee</strong> Shares (as set forth in the Equity Agreement) that are within the reasonable control of Intrexon have been satisfied or waived, the issuance of the <strong>Technology Access Fee</strong> Shares (as set forth in the Equity Agreement) is a condition subsequent to the effectiveness of this Agreement.", "As set forth in the Equity Agreements, the <strong>Technology Access Fee</strong> will be that number of shares of Fibrocell common stock having a value equaling $3,293,800 (the number of shares to be calculated according to the terms of the Equity Agreements), and such shares issuance will occur contemporaneously with the execution of this Agreement and the Equity Agreements.", "Payment of the <strong>Technology Access Fee</strong> shall be subject to any withholding Tax obligations set forth in Section 6.9.1.", "Subject to the terms and conditions of this Agreement, the Channel Agreement and in reliance upon the representations, warranties and agreements contained herein, the Company will issue to Intrexon the <strong>Technology Access Fee</strong> Shares.", "The Parties agree that the consideration received by the Company hereunder shall be the execution and delivery by Intrexon of the Channel Agreement which consideration is at least equal to the par value of the <strong>Technology Access Fee</strong> Shares issued hereunder.", "Provided that all closing conditions for the <strong>Technology Access Fee</strong> Shares (as defined in the Equity Agreement) that are within the reasonable control of Intrexon have been satisfied or waived, the payment of the <strong>Technology Access fee</strong> to Intrexon, including issuance of any <strong>Technology Access Fee</strong> Shares (as set forth in the Equity Agreement) to Intrexon, is a condition subsequent to the effectiveness of this Agreement.", "Arcadia shall receive from Mahyco a <strong>Technology Access Fee</strong> of [\u2026*\u2026] upon signature of the Agreement.", "As set forth in the Equity Agreement, the <strong>Technology Access Fee</strong> will be either (i) one and one-half million dollars ($1,500,000) in cash, or (ii) that number of shares of Soligenix common stock having a value equaling one and one-half million dollars ($1,500,000) (the number of shares to be calculated according to, or stipulated by, the terms of the Equity Agreement)."], "related": [["access-fee", "Access Fee", "Access Fee"], ["maintenance-and-support-services", "Maintenance and Support Services", "Maintenance and Support Services"], ["clean-coal-technology-demonstration-project", "Clean coal technology demonstration project", "Clean coal technology demonstration project"], ["support-and-maintenance-services", "Support and Maintenance Services", "Support and Maintenance Services"], ["license-fee", "License Fee", "License Fee"]], "related_snippets": [], "updated": "2025-07-23T06:14:10+00:00"}, "json": true, "cursor": ""}}